echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Science Sub-Journal: Platelets are the key to vascular injury in patients with COVID-19

    Science Sub-Journal: Platelets are the key to vascular injury in patients with COVID-19

    • Last Update: 2021-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A new study found that abnormal crosstalk between platelets and vascular intimal cells is one of the causes of fatal organ damage in patients with severe COVID-19


    The study, led by researchers at New York University’s Grossman School of Medicine, revealed protein signals from platelets and cell fragments.


    This study was published in the online edition of Science Advances on September 8.


    In order to support the theory that platelets are the core of vascular damage in COVID-19, the research team also presented evidence that drugs (clopidogrel or ticagrelor) that block platelet activation through platelet surface protein P2Y12 are known to reduce COVID-19 related Inflammation of blood vessels


    "Our findings reveal a new role in COVID-19 blood vessel damage, platelets, which may explain to a large extent the COVID-19 virus is more deadly than its relatives, causing the common cold," said corresponding author Tai · Dr.


    Better understanding

    The authors of the study said that abnormal systemic inflammation and blood clotting were identified as the core features of severe COVID-19 early in the pandemic, and the two are considered to be interrelated


    In the current study, small blood vessel endothelial cells were exposed to the fluid released by platelets from COVID-19 patients or healthy similar patients (control group)


    Through cross-comparison with the database, from the initial large list of potential culprits, the candidate list was reduced to two related genetic material fragments: S100A8 and S100A9, which coded for the construction of MRP 8 and 14


    In addition, the research team also found that platelet-driven endothelial damage and abnormal coagulation may occur through the action of p-selectin in the platelet component alpha particles


    Researchers also found that anticoagulant P2Y12 inhibitors reduced the expression of S100A8 and S100A9 in platelets by 18% within 4 weeks, preventing COVID-19 platelets from inducing vascular damage in laboratory tests


    "The current research supports the theory that platelets activate endothelial cells through p-selectin.


    Berger said that ACTIV-4a will also soon begin testing the effects of a p-selectin inhibitor called crizanlizumab in COVID-19 hospitalized patients


    Original search:

    Platelets Amplify Endotheliopathy in COVID-19

    10.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.